Anlotinib Capsules in the Treatment for IPF/PF-ILDs

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 28, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Interstitial Lung Diseases
Interventions
DRUG

Anlotinib

"Drug: Anlotinib The dose of nintedanib hydrochloride is 8mg per dose, taken orally once daily before breakfast. The drug is taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.~Drug: Placebo Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up."

DRUG

Placebo

Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.

Trial Locations (1)

325000

RECRUITING

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

First Affiliated Hospital of Wenzhou Medical University

OTHER